Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research — the drugs that slow decline, the science of regeneration, and the mind-body work, graded honestly.
Latest brief · 2026-08-10
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
This is a new trial that is just starting. It will test a drug called AP306 in adults on dialysis who have too much phosphate in their blood. High phosphate is common in dialysis and can harm the heart and bones. The study checks if the drug is safe and lowers phosphate, and there are no results yet.
Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease
This trial is starting. It tests whether pushing blood pressure down harder, using water pills (diuretics), works better than usual care. The people have moderate to severe kidney disease and high blood pressure that is not controlled. Lower blood pressure protects kidneys over time, but this study has no results yet.
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
This trial is starting. It tests a pill called empagliflozin against a placebo (a dummy pill) in children ages 2 to 17 with kidney disease. This drug already helps adults with kidney disease. The study will see if it is safe and helps children, and there are no results yet.
The role of gut microbiome disruption in the development of metabolic dysfunction-associated kidney disease.
This is a review of how an unhealthy balance of gut bacteria may play a part in metabolic kidney disease. A review gathers other work; it is not a new experiment. It points to the gut as a possible target but proves nothing on its own.
Association Between Dietary Magnesium Intake and All-Cause Mortality in Patients with Chronic Kidney Disease: Insights from NHANES 1999-2018.
This study used a large US health survey to link diet magnesium with the risk of dying in people with kidney disease. People who ate more magnesium tended to live longer. This is an observational link, not proof, and diet surveys can be inexact.
Regulatory Frameworks and Technical Bottlenecks for Clinical Translation of the Bioartificial Kidney.
This is an expert review of the rules and technical hurdles to bringing a bioartificial kidney (a lab-built kidney-replacing device) to patients. It maps what still blocks the path to the clinic. It is opinion and background, not a test of the device.
Proteomic Identification of Pig Xenoantigens for Clinical Xenotransplantation.
This lab study found proteins on pig cells that the human immune system would attack. Knowing these targets could help make pig organs safer for transplant into people. This work was done in the lab, not in patients yet.
Implementation of KDIGO CKD Screening and Its Prognostic Implications in Community-Dwelling Adults Aged 75 Years or Older: A Population-Based Cohort Study
This large community study checked how well a standard kidney-screening approach (KDIGO) worked in adults aged 75 and older. It found the screening helped predict who was at risk of harm. This is an observational cohort, so it shows patterns, not proof of cause.